Breast Cancer: Biomarkers and Clinical Management

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 1956

Special Issue Editors


E-Mail Website
Guest Editor
Radiology Unit, Mater Olbia Hospital (Qatar Foundation Endowment and Policlinico Universitario Agostino Gemelli IRCCS Foundation), Strada Statale 125 Orientale Sarda, 07026 Olbia, Italy
Interests: breast radiology; mammography; breast ultrasound; breast MRI; oncological radiology; abdominal and pelvic ultrasound (US) and US Doppler; osteo-articular ultrasound; endocavitary ultrasound; Computed Tomography (CT); CT angiography, including cardio-vascular imaging

E-Mail Website
Guest Editor
Oncology Unit, Mater Olbia Hospital, Olbia, Italy
Interests: breast cancer; triple negative breast cancer; HER2 positive; immunotherapy; targeted therapy; gynecological cancer

E-Mail Website
Guest Editor Assistant
Radiology Unit, Mater Olbia Hospital, Olbia, Italy
Interests: artificial intelligence; mammography with contrast; MRI diffusion sequences

Special Issue Information

Dear Colleagues,

In reference to global epidemiological data, which indicate an increasing incidence of breast cancer, especially in younger female population groups, and the concomitant technological advancement in early detection (radiological imaging, pathological anatomy, and genetics, for example), in order to anticipate tumor detection, in very dense and young breasts, we are pleased to invite the scientific community and experts in this field to present their innovative research and studies in the following areas:

- Imaging: CEM (contrast enhancement mammography)
- Imaging: MRI (screening and ultrafast MRI and DWI) in young women
- New protocols and guidelines
- The application of AI algorithms for detection and biopsy guidance
- Advanced genetic screening techniques
- Clinical and genetic biomarkers
- Genomics and radiomics for the identification of therapeutic targets
- Analysis of the correlation between tumor occurrence and gut bacterial flora patterns
- Advances in anatomic pathology
- Personalized medicine for the treatment of breast cancer
- Advances in therapeutic lines (in situ Ca,B3)
- New surgical approaches
- New non-surgical approaches (cryoablation techniques, for example)
- New radiotherapy approaches
- New medical therapy approaches (chemotherapy and immunotherapy)

We welcome the cooperation of all researchers dedicated to advancing the field in question.

Dr. Pierluigi Maria Rinaldi
Dr. Antonella Lai
Guest Editors

Dr. Rino Aldo Montella
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • triple-negative breast cancer
  • targeted therapy
  • inhibitors
  • breast cancer biomarkers
  • immune therapy
  • personalized medicine
  • mammography with contrast medium
  • magnetic resonance imaging
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2739 KiB  
Article
Low CDKN1B Expression Associated with Reduced CD8+ T Lymphocytes Predicts Poor Outcome in Breast Cancer in a Machine Learning Analysis
by Hyung-Suk Kim, Yung-Kyun Noh, Kyueng-Whan Min and Dong-Hoon Kim
J. Pers. Med. 2024, 14(1), 30; https://doi.org/10.3390/jpm14010030 - 25 Dec 2023
Viewed by 1608
Abstract
The cyclin-dependent kinase inhibitor 1B (CDKN1B) gene, which encodes the p27Kip1 protein, is important in regulating the cell cycle process and cell proliferation. Its role in breast cancer prognosis is controversial. We evaluated the significance and predictive role of CDKN1B expression in breast [...] Read more.
The cyclin-dependent kinase inhibitor 1B (CDKN1B) gene, which encodes the p27Kip1 protein, is important in regulating the cell cycle process and cell proliferation. Its role in breast cancer prognosis is controversial. We evaluated the significance and predictive role of CDKN1B expression in breast cancer prognosis. We investigated the clinicopathologic factors, survival rates, immune cells, gene sets, and prognostic models according to CDKN1B expression in 3794 breast cancer patients. We performed gene set enrichment analysis (GSEA), in silico cytometry, pathway network analyses, gradient boosting machine (GBM) learning, and in vitro drug screening. High CDKN1B expression levels in breast cancer correlated with high lymphocyte infiltration signature scores and increased CD8+ T cells, both of which were associated with improved prognosis in breast cancer. which were associated with a better prognosis. CDKN1B expression was associated with gene sets for the upregulation of T-cell receptor signaling pathways and downregulation of CD8+ T cells. Pathway network analysis revealed a direct link between CDKN1B and the pathway involved in the positive regulation of the protein catabolic process pathway. In addition, an indirect link was identified between CDKN1B and the T-cell receptor signaling pathway. In in vitro drug screening, BMS-345541 demonstrated efficacy as a therapeutic targeting of CDKN1B, effectively impeding the growth of breast cancer cells characterized by low CDKN1B expression. The inclusion of CDKN1B expression in GBM models increased the accuracy of survival predictions. CDKN1B expression plays a significant role in breast cancer progression, implying that targeting CDKN1B might be a promising strategy for treating breast cancer. Full article
(This article belongs to the Special Issue Breast Cancer: Biomarkers and Clinical Management)
Show Figures

Graphical abstract

Back to TopTop